Rachael I Scahill

List of Publications by Year
in descending order

110 papers	9,245 citations	109321 35 h-index	49909 87 g-index
128 all docs	128 docs citations	128 times ranked	8799 citing authors

#	Article	IF	Citations
1	Huntington disease. Nature Reviews Disease Primers, 2015, 1, 15005.	30.5	1,031
2	Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology, 2014, 10, 204-216.	10.1	873
3	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurology, The, 2009, 8, 791-801.	10.2	856
4	A Longitudinal Study of Brain Volume Changes in Normal Aging Using Serial Registered Magnetic Resonance Imaging. Archives of Neurology, 2003, 60, 989.	4.5	736
5	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurology, The, 2013, 12, 637-649.	10.2	704
6	Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4703-4707.	7.1	613
7	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurology, The, 2011, 10, 31-42.	10.2	530
8	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurology, The, 2012, 11, 42-53.	10.2	479
9	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurology, The, 2017, 16, 601-609.	10.2	272
10	An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease. NeuroImage, 2012, 60, 1880-1889.	4.2	192
11	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntingtonâ€™s disease. Science Translational Medicine, 2018, 10, .	12.4	134
12	Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. Neurobiology of Disease, 2015, 83, 115-121.	4.4	133
13	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine, 2015, 2, 1420-1429.	6.1	122
14	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurology, The, 2020, 19, 502-512.	10.2	122
15	Early atrophy of pallidum and accumbens nucleus in Huntingtonâ€™s disease. Journal of Neurology, 2011, 258, 412-420.	3.6	121
16	MSH3 modifies somatic instability and disease severity in Huntingtonâ€™s and myotonic dystrophy type 1. Brain, 2019, 142, 1876-1886.	7.6	114
17	Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Human Brain Mapping, 2013, 34, 519-529.	3.6	113
18	The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 756-763.	1.9	105

#	Article	IF	Citations
19	Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntingtonâ€™s disease. Brain, 2015, 138, 3327-3344.	7.6	96
20	Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. Lancet Neurology, The, 2022, 21, 645-658.	10.2	96
21	Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia, 2008, 46, 2152-2160.	1.6	93
22	Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neuroscience and Biobehavioral Reviews, 2013, 37, 480-490.	6.1	81
23	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology, 2018, 90, e717-e723.	1.1	65
24	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntingtonâ€™s disease. Science Translational Medicine, 2020, 12, .	12.4	64
25	Operationalizing compensation over time in neurodegenerative disease. Brain, 2017, 140, 1158-1165.	7.6	62
26	White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression. Cortex, 2014, 52, 98-112.	2.4	57
27	The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. Movement Disorders, 2011, 26, 1684-1690.	3.9	56
28	The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. Neuropsychologia, 2015, 79, 138-146.	1.6	56
29	In vivo characterization of white matter pathology in premanifest huntington's disease. Annals of Neurology, 2018, 84, 497-504.	5.3	53
30	An imageâ€based model of brain volume biomarker changes in Huntington's disease. Annals of Clinical and Translational Neurology, 2018, 5, 570-582.	3.7	50
31	Automated quantification of caudate atrophy by local registration of serial MRI: Evaluation and application in Huntington's disease. NeuroImage, 2009, 47, 1659-1665.	4.2	46
32	The Dementias Platform UK (DPUK) Data Portal. European Journal of Epidemiology, 2020, 35, 601-611.	5.7	45
33	Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntingtonâ€™s Disease. Journal of the International Neuropsychological Society, 2016, 22, 595-608.	1.8	44
34	Association of CAG Repeats With Long-term Progression in Huntington Disease. JAMA Neurology, 2019, 76, 1375.	9.0	44
35	Fluid and imaging biomarkers for Huntington's disease. Molecular and Cellular Neurosciences, 2019, 97, 67-80.	2.2	41
36	Correction of inter-scanner and within-subject variance in structural MRI based automated diagnosing. NeuroImage, 2014, 98, 405-415.	4.2	40

#	Article	IF	Citations
37	White matter predicts functional connectivity in premanifest Huntington's disease. Annals of Clinical and Translational Neurology, 2017, 4, 106-118.	3.7	38
38	Topological length of white matter connections predicts their rate of atrophy in premanifest Huntingtonâ€™s disease. JCI Insight, 2017, 2, .	5.0	37
39	Genetic Influences on Atrophy Patterns in Familial Alzheimer's Disease: A Comparison of APP and PSEN1 Mutations. Journal of Alzheimer's Disease, 2013, 35, 199-212.	2.6	36
40	Evaluation of multi-modal, multi-site neuroimaging measures in Huntington's disease: Baseline results from the PADDINGTON study. NeuroImage: Clinical, 2013, 2, 204-211.	2.7	34
41	Neuropsychiatry and White Matter Microstructure in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 239-249.	1.9	33
42	Testing a longitudinal compensation model in premanifest Huntingtonâ€™s disease. Brain, 2018, 141, 2156-2166.	7.6	33
43	Dynamics of Cortical Degeneration Over a Decade in Huntingtonâ€™s Disease. Biological Psychiatry, 2021, 89, 807-816.	1.3	32
44	Longitudinal Diffusion Tensor Imaging Shows Progressive Changes in White Matter in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 333-346.	1.9	31
45	Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntingtonâ€™s Disease. Frontiers in Neurology, 2017, 8, 519.	2.4	31
46	Corpus Callosal Atrophy in Premanifest and Early Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 517-526.	1.9	29
47	Embodied emotion impairment in Huntington's Disease. Cortex, 2017, 92, 44-56.	2.4	28
48	Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease. Human Brain Mapping, 2017, 38, 2819-2829.	3.6	28
49	Predicting clinical diagnosis in Huntington's disease: An imaging polymarker. Annals of Neurology, 2018, 83, 532-543.	5.3	26
50	Fronto-striatal circuits for cognitive flexibility in far from onset Huntingtonâ€™s disease: evidence from the Young Adult Study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 143-149.	1.9	26
51	Cerebrospinal fluid neurogranin and TREM2 in Huntingtonâ€™s disease. Scientific Reports, 2018, 8, 4260.	3.3	25
52	Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. NeuroImage: Clinical, 2018, 17, 312-324.	2.7	23
53	Short-interval observational data to inform clinical trial design in Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1291-1298.	1.9	22
54	Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease. Annals of Neurology, 2020, 87, 751-762.	5.3	22

#	Article	IF	Citations
55	Diffusion imaging in Huntingtonâ€™s disease: comprehensive review. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 62-69.	1.9	22
56	Inconsistent emotion recognition deficits across stimulus modalities in Huntington×³s disease. Neuropsychologia, 2014, 64, 99-104.	1.6	20
57	Characterizing White Matter in Huntington's Disease. Movement Disorders Clinical Practice, 2020, 7, 52-60.	1.5	20
58	Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study. EBioMedicine, 2021, 65, 103266.	6.1	20
59	Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease. Neurology: Genetics, 2021, 7, e617.	1.9	20
60	Natural biological variation of white matter microstructure is accentuated in Huntington's disease. Human Brain Mapping, 2018, 39, 3516-3527.	3.6	19
61	Biomarker development for Huntington's disease. Drug Discovery Today, 2014, 19, 972-979.	6.4	18
62	Natural variation in sensoryâ€motor white matter organization influences manifestations of Huntington's disease. Human Brain Mapping, 2016, 37, 4615-4628.	3.6	18
63	Structural imaging in premanifest and manifest Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 144, 247-261.	1.8	18
64	Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. Journal of Neurochemistry, 2021, 158, 539-553.	3.9	18
65	Longitudinal Neuroimaging Biomarkers in Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 21-39.	1.9	16
66	Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study. NeuroImage: Clinical, 2018, 19, 66-70.	2.7	14
67	Quantification of huntingtin protein species in Huntingtonâ€™s disease patient leukocytes using optimised electrochemiluminescence immunoassays. PLoS ONE, 2017, 12, e0189891.	2.5	14
68	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. JAMA Neurology, 2017, 74, 1352.	9.0	12
69	Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntingtonâ€™s disease. Scientific Reports, 2021, 11, 3481.	3.3	12
70	Composite <scp>UHDRS</scp> Correlates With Progression of Imaging Biomarkers in Huntington's Disease. Movement Disorders, 2021, 36, 1259-1264.	3.9	12
71	Design optimization for clinical trials in earlyâ€stage manifest Huntington's disease. Movement Disorders, 2017, 32, 1610-1619.	3.9	11
72	Test-Retest Reliability of Diffusion Tensor Imaging in Huntingtonâ€™s Disease. PLOS Currents, 2014, 6, .	1.4	11

#	Article	IF	Citations
73	Timing of selective basal ganglia white matter loss in premanifest Huntingtonâ€™s disease. NeuroImage: Clinical, 2022, 33, 102927.	2.7	10
74	Biomarkers for Huntington's disease: an update. Expert Opinion on Medical Diagnostics, 2012, 6, 371-375.	1.6	9
75	Functional Magnetic Resonance Imaging in Huntington's Disease. International Review of Neurobiology, 2018, 142, 381-408.	2.0	6
76	Apathy Associated With Impaired Recognition of Happy Facial Expressions in Huntingtonâ€™s Disease. Journal of the International Neuropsychological Society, 2019, 25, 453-461.	1.8	6
77	Identifying diseaseâ€associated biomarker network features through conditional graphical model. Biometrics, 2020, 76, 995-1006.	1.4	6
78	Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast <scp>MRI</scp>. European Journal of Neuroscience, 2019, 49, 1632-1639.	2.6	5
79	Longitudinal Structural <scp>MRI</scp> in Neurologically Healthy Adults. Journal of Magnetic Resonance Imaging, 2020, 52, 1385-1399.	3.4	5
80	Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials. Frontiers in Neurology, 2021, 12, 712565.	2.4	5
81	Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntingtonâ€™s Disease. Frontiers in Neurology, 2021, 12, 616272.	2.4	3
82	Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review. Frontiers in Neurology, 2021, 12, 712555.	2.4	3
83	Neurofilament light-associated connectivity in young-adult Huntingtonâ€™s disease is related to neuronal genes. Brain, 2022, 145, 3953-3967.	7.6	3
84	Magnetic Resonance Imaging in Huntingtonâ€™s Disease. Methods in Molecular Biology, 2018, 1780, 303-328.	0.9	2
85	A Multi-Study Model-Based Evaluation of the Sequence of Imaging and Clinical Biomarker Changes in Huntingtonâ€™s Disease. Frontiers in Big Data, 2021, 4, 662200.	2.9	2
86	Aberrant Striatal Value Representation in Huntington's Disease Gene Carriers 25 Years Before Onset. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 910-918.	1.5	1
87	Patterns of cerebral atrophy in Alzheimer's disease and semantic dementia: A comparison of voxel based morphometry and region of interest measurements. NeuroImage, 2001, 13, 317.	4.2	0
88	P3-062 Predictors and correlates of inter-individual variation in MRI derived atrophy rates in Alzheimer's disease. Neurobiology of Aging, 2004, 25, S369.	3.1	0
89	Recent advances in imaging the onset and progression of Huntingtonâ€™s disease. Neurodegenerative Disease Management, 2013, 3, 241-252.	2.2	0
90	D16â€...White matter microstructure and natural biological variation in huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A39.2-A39.	1.9	0

#	Article	IF	Citations
91	D18â€...Brain network breakdown and pathophysiological correlates in huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A40.2-A40.	1.9	0
92	D21â€...Longitudinal compensation in the cognitive network in huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A42.1-A42.	1.9	0
93	D9â€...An evaluation of methods for the volumetric measurement of grey matter in huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A37.1-A37.	1.9	0
94	D20â€...Operationalising compensation over time in neurodegenerative disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A41.2-A41.	1.9	0
95	D22â€...Compensation in preclinical huntingtonâ€™s disease: evidence from the track-on HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A42.2-A42.	1.9	0
96	1609â€...Length of white matter connexions determine their rate of atrophy in premanifest huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A9.2-A9.	1.9	0
97	D10â€...Neurofilament light protein in blood predicts regional atrophy in huntingtonâ€™s disease. , 2018, , .		0
98	E11â€...Compensation in huntingtonâ€™s disease. , 2018, , .		0
99	F22â€...Robust biomarkers of huntingtonâ€™s disease progression: observations from the track-hd, predict-hd and image-hd studies. , 2018, , .		0
100	F45â€...Apathy associated with impaired recognition of happy facial expressions in huntingtonâ€™s disease. , 2018, , .		0
101	D09â€...Parallel evaluation of mutant huntingtin and neurofilament light as biomarkers for huntingtonâ€™s disease: the hd-csf study. , 2018, , .		0
102	Multimodal characterization of the visual network in Huntingtonâ€™s disease gene carriers. Clinical Neurophysiology, 2019, 130, 2053-2059.	1.5	0
103	Automated Segmentation of Cortical Grey Matter from T1-Weighted MRI Images. Journal of Visualized Experiments, 2019, , .	0.3	0
104	F05â€...Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis. , 2021, , .		0
105	Automated Hippocampal Segmentation by Regional Fluid Registration of Serial MRI: Validation and Application in Alzheimer.s Disease. Lecture Notes in Computer Science, 2001, , 1298-1299.	1.3	0
106	E01â€...Modelling the trajectory of cortical atrophy in huntingtonâ€™s disease. , 2018, , .		0
107	F21â€...Cag-dependent huntingtonâ€™s disease patterns over decades: the track-hd and track-on studies. , 2018, , .		0
108	E07â€...Cerebrospinal fluid flow dynamics in huntingtonâ€™s disease using phase contrast MRI: a pilot cross-sectional study. , 2018, , .		0

#	Article	IF	Citations
109	F59â€…Huntingtonâ€™s disease young adult study (HD-YAS). , 2018, , .		0
110	D08â€…Neurofilament light protein in blood as a potential biomarker of neurodegeneration in hungtingtonâ€™s disease: a retrospective cohort analysis. , 2018, , .		0